NO971860L - Matrikstablett som tillater en forlenget frigivelse av natriumsaltet av tianeptin etter oral administrasjon - Google Patents

Matrikstablett som tillater en forlenget frigivelse av natriumsaltet av tianeptin etter oral administrasjon

Info

Publication number
NO971860L
NO971860L NO971860A NO971860A NO971860L NO 971860 L NO971860 L NO 971860L NO 971860 A NO971860 A NO 971860A NO 971860 A NO971860 A NO 971860A NO 971860 L NO971860 L NO 971860L
Authority
NO
Norway
Prior art keywords
tianeptin
oral administration
sodium salt
prolonged release
matrix tablet
Prior art date
Application number
NO971860A
Other languages
English (en)
Other versions
NO971860D0 (no
NO315407B1 (no
Inventor
Bruno Huet De Barochez
Patrick Wuethrich
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of NO971860D0 publication Critical patent/NO971860D0/no
Publication of NO971860L publication Critical patent/NO971860L/no
Publication of NO315407B1 publication Critical patent/NO315407B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
NO19971860A 1996-04-24 1997-04-23 Matrikstablett for forlenget frigivelse av natriumsaltet av tianeptin og dens fremstilling NO315407B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9605174A FR2747921B1 (fr) 1996-04-24 1996-04-24 Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale

Publications (3)

Publication Number Publication Date
NO971860D0 NO971860D0 (no) 1997-04-23
NO971860L true NO971860L (no) 1997-10-27
NO315407B1 NO315407B1 (no) 2003-09-01

Family

ID=9491549

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971860A NO315407B1 (no) 1996-04-24 1997-04-23 Matrikstablett for forlenget frigivelse av natriumsaltet av tianeptin og dens fremstilling

Country Status (18)

Country Link
US (1) US5888542A (no)
EP (1) EP0803253B1 (no)
JP (1) JPH1036268A (no)
CN (1) CN1116029C (no)
AT (1) ATE205715T1 (no)
AU (1) AU719822B2 (no)
CA (1) CA2203310C (no)
DE (1) DE69706748T2 (no)
DK (1) DK0803253T3 (no)
ES (1) ES2164310T3 (no)
FR (1) FR2747921B1 (no)
GR (1) GR3037043T3 (no)
HU (1) HU224192B1 (no)
NO (1) NO315407B1 (no)
NZ (1) NZ314662A (no)
PL (1) PL188135B1 (no)
PT (1) PT803253E (no)
ZA (1) ZA973495B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2791891A1 (fr) * 1999-04-07 2000-10-13 Adir Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
US6683072B1 (en) 2003-02-04 2004-01-27 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of irritable bowel syndrome and nonulcer dyspepsia
ATE454138T1 (de) * 2003-08-08 2010-01-15 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
US20100304391A1 (en) * 2009-05-29 2010-12-02 Lombard Jay L Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
KR20120092993A (ko) * 2011-02-14 2012-08-22 지엘팜텍 주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
EP2561864B1 (en) * 2011-08-25 2014-12-31 Zaklady Farmaceutyczne Polpharma SA Coated tablet comprising tianeptine and process for preparation thereof
KR101136976B1 (ko) * 2011-09-06 2012-05-30 건일제약 주식회사 티아넵틴 또는 그의 염을 포함하는 탈모증의 예방 또는 치료용 약학 조성물
GB201208315D0 (en) 2012-05-11 2012-06-27 Numedicus Ltd Pharmaceutical methods and compositions
CN104031005B (zh) * 2014-05-30 2016-04-27 济南诚汇双达化工有限公司 一种噻萘普汀钠中间体的制备方法
KR20180101307A (ko) 2018-09-04 2018-09-12 지엘팜텍주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
KR20200104265A (ko) 2020-08-21 2020-09-03 지엘팜텍주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
FR2635461B1 (fr) * 1988-08-18 1992-01-17 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
FR2716623B1 (fr) * 1994-02-25 1996-08-23 Adir Utilisation d'un dérivé tricyclique pour l'obtention de médicaments destinés au traitement des troubles mnémo-cognitifs.

Also Published As

Publication number Publication date
HUP9700806A3 (en) 2000-01-28
FR2747921B1 (fr) 1998-10-30
PT803253E (pt) 2001-12-28
HU224192B1 (hu) 2005-06-28
ATE205715T1 (de) 2001-10-15
CN1168792A (zh) 1997-12-31
PL319627A1 (en) 1997-10-27
US5888542A (en) 1999-03-30
EP0803253B1 (fr) 2001-09-19
NO971860D0 (no) 1997-04-23
EP0803253A1 (fr) 1997-10-29
CA2203310A1 (fr) 1997-10-24
DE69706748D1 (de) 2001-10-25
AU719822B2 (en) 2000-05-18
AU1904197A (en) 1997-10-30
HUP9700806A2 (hu) 1998-10-28
ZA973495B (en) 1997-11-18
GR3037043T3 (en) 2002-01-31
NO315407B1 (no) 2003-09-01
DK0803253T3 (da) 2001-11-19
HU9700806D0 (en) 1997-06-30
NZ314662A (en) 1998-12-23
JPH1036268A (ja) 1998-02-10
ES2164310T3 (es) 2002-02-16
FR2747921A1 (fr) 1997-10-31
CA2203310C (fr) 2001-10-23
DE69706748T2 (de) 2002-07-04
CN1116029C (zh) 2003-07-30
PL188135B1 (pl) 2004-12-31

Similar Documents

Publication Publication Date Title
NO971860D0 (no) Matrikstablett som tillater en forlenget frigivelse av natriumsaltet av tianeptin etter oral administrasjon
PT781550E (pt) Composicao farmaceutica bioadesiva para a libertacao controlada de principios activos
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
HUP9902194A2 (hu) Dibenzo-[b,f][1,4]tiazepin-származékot tartalmazó gyógyászati készítmények
DK1375503T3 (da) Dioxinoderivater og deres anvendelse som dopaminagonister
ATE397441T1 (de) Schmelzextrudierte oral verabreichbare hydromorphoneformulierungen
DE69621885D1 (de) Neue galenische orale pharmazeutische formulierung
AU7052798A (en) Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates
AU7052698A (en) Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates
DE69726179D1 (de) Pharmazeutische suspensionssysteme
ATE312602T1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
FI951357A (fi) Farmaseuttiset koostumukset, jotka mahdollistavat trimetatsidiinin hidastetun vapautumisen oraalisen annostuksen jälkeen
DK0519820T3 (da) Matrixtablet, som muliggør længerevarende frigivelse af indapamid efter oral administration
DE69625189D1 (de) Tablette mit gesteuerter freisetzung
EA200001201A2 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
HRP20010684B1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
NO980923D0 (no) Optisk aktivt fenylpyrimidin-derivat som analgetisk middel
FR2745500B1 (fr) Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
ITMI951933A0 (it) Impianto orale antirotazione
BR1100929A (pt) Derivados 1,2-difenilpirrol e uma composição farmacêutica

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees